Eli Lilly & Co. posted a 4% decline in second-quarter revenue, as a drop in sales of the company’s Covid-19 antibody treatment and some older drugs offset gains in sales for newer drugs.
The pharmaceutical company Thursday reiterated its sales forecast for the year but cut its profit outlook as the stronger U.S. dollar hurts results.